WO2010141093A3 - Méthodes de co-signalement permettant de traiter les cancers - Google Patents

Méthodes de co-signalement permettant de traiter les cancers Download PDF

Info

Publication number
WO2010141093A3
WO2010141093A3 PCT/US2010/001625 US2010001625W WO2010141093A3 WO 2010141093 A3 WO2010141093 A3 WO 2010141093A3 US 2010001625 W US2010001625 W US 2010001625W WO 2010141093 A3 WO2010141093 A3 WO 2010141093A3
Authority
WO
WIPO (PCT)
Prior art keywords
individual
lymphocytes
administering
neoplastic disease
treating cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/001625
Other languages
English (en)
Other versions
WO2010141093A2 (fr
Inventor
Scott E. Strome
Dan H. Schulze
Andrei Chapoval
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
University of Maryland College Park
Original Assignee
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, University of Maryland College Park filed Critical University of Maryland Baltimore
Publication of WO2010141093A2 publication Critical patent/WO2010141093A2/fr
Publication of WO2010141093A3 publication Critical patent/WO2010141093A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une méthode de traitement d'une maladie néoplasique chez un individu ayant besoin d'un tel traitement, ladite méthode comprenant les étapes consistant à multiplier des lymphocytes T γδ in vitro ; à sensibiliser des cellules NK in vitro ; et à administrer lesdits lymphocytes T γδ multipliés et lesdites cellules NK sensibilisées audit individu, avec pour résultat un effet cytotoxique ou cytolytique. L'invention concerne, en outre, une méthode de traitement d'une maladie néoplasique chez un individu ayant besoin d'un tel traitement, ladite méthode comprenant les étapes consistant à administrer audit individu un composé capable d'activer les lymphocytes T yδ, puis un anticorps dirigé contre un antigène tumoral associé à ladite maladie néoplasique.
PCT/US2010/001625 2009-06-04 2010-06-04 Méthodes de co-signalement permettant de traiter les cancers Ceased WO2010141093A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18400009P 2009-06-04 2009-06-04
US61/184,000 2009-06-04

Publications (2)

Publication Number Publication Date
WO2010141093A2 WO2010141093A2 (fr) 2010-12-09
WO2010141093A3 true WO2010141093A3 (fr) 2011-04-21

Family

ID=43298366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001625 Ceased WO2010141093A2 (fr) 2009-06-04 2010-06-04 Méthodes de co-signalement permettant de traiter les cancers

Country Status (1)

Country Link
WO (1) WO2010141093A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2012099093A1 (fr) * 2011-01-21 2012-07-26 株式会社日本バイオセラピー研究所 Procédé pour la production de préparation du sang enrichi en cellules nk
EP2852409B1 (fr) * 2012-05-23 2020-03-25 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 pour le traitement du cancer
WO2013174404A1 (fr) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2013174403A1 (fr) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
CN102899289B (zh) * 2012-10-24 2014-09-03 扬州维克斯生物科技有限公司 一种超级cik杀伤细胞的制备方法
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014127785A1 (fr) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
US10233425B2 (en) * 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
WO2020143042A1 (fr) * 2019-01-11 2020-07-16 深圳市双科生物科技有限公司 Procédé de restauration de fonction cellulaire
CN110283785A (zh) * 2019-05-16 2019-09-27 安徽瑞达健康产业有限公司 一种γδT-NK细胞共培养的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US20050164306A1 (en) * 2002-04-19 2005-07-28 Adrien Beaudoin Methods for screening for a compound useful in the treatment or prevention of lymphocytic disorders, for inhibiting lymphocite activity and preventing or treating lymphocytic disorders
US20080199475A1 (en) * 2006-11-27 2008-08-21 Patrys Limited Novel glycosylated peptide target in neoplastic cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US20050164306A1 (en) * 2002-04-19 2005-07-28 Adrien Beaudoin Methods for screening for a compound useful in the treatment or prevention of lymphocytic disorders, for inhibiting lymphocite activity and preventing or treating lymphocytic disorders
US20080199475A1 (en) * 2006-11-27 2008-08-21 Patrys Limited Novel glycosylated peptide target in neoplastic cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEXANDER A.A. ET AL: "Isopentenyl pyrophosphate-activated CD56+{gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma", CLIN CANCER RES., vol. 14, no. 13, July 2008 (2008-07-01), pages 4232 - 4240 *

Also Published As

Publication number Publication date
WO2010141093A2 (fr) 2010-12-09

Similar Documents

Publication Publication Date Title
WO2010141093A3 (fr) Méthodes de co-signalement permettant de traiter les cancers
BR112019009925A2 (pt) método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .
WO2013088148A3 (fr) Méthode de traitement à l'aide d'un produit à base de lymphocytes t thérapeutiques provenant de donneurs mobilisés
WO2011053750A3 (fr) Immunothérapie pharmacorésistante pour le traitement d'un cancer
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
WO2011112953A3 (fr) Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples négatifs et de type basal
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
IL276515B1 (en) PD–L1-specific antibodies and methods of using them
PE20141937A1 (es) Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
WO2007089945A3 (fr) Méthodes de traitement de maladies par ciblage du ilt3
WO2012177595A9 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer
WO2008039874A3 (fr) Vaccins comprenant des antigènes de cellules souches cancéreuses et procédés
MY161724A (en) Therapeutic canine immunoglobulins and methods of using the same
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
HK1200716A1 (zh) 使用胞苷類似物的口服製劑治療癌症的方法
WO2007016130A3 (fr) Methode de traitement de cellules cancereuses pour creer une cellule cancereuse modifiee provoquant une reponse immunogene
PE20130387A1 (es) Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria
WO2013104050A3 (fr) Procédé de traitement du cancer du sein
WO2007130555A3 (fr) Augmentation de la réaction immunitaire au vaccin contre le cancer
MX2019015194A (es) Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
WO2017076360A8 (fr) Polythérapie pour maladies malignes
WO2022229884A3 (fr) Cellules de présentation d'antigène recombinant
WO2015157299A3 (fr) Inhibition de la liaison à, l'incorporation, l'internalisation et/ou l'endocytose de lactate-déshydrogénase 5 (ldh-5) dans des cellules immunitaires
JP2019517507A5 (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10783712

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10783712

Country of ref document: EP

Kind code of ref document: A2